Trimble launches new software solution to enhance construction cost control
US technology company Trimble has launched its new software solution, Trimble Materials, aimed at enhancing contractors' control over material costs through improved budgeting and inventory tracking.
This end-to-end purchasing, inventory, and accounts payable solution is designed to centralise and streamline the entire purchasing and materials management process for contractors.
Trimble vice-president and general manager of construction management solutions Lawrence Smith said: "Managing numerous material orders from various suppliers amidst volatile pricing and availability presents significant challenges in the construction sector.
"Trimble Materials offers a cohesive solution by connecting material ordering, inventory and accounting, which is especially valuable in the face of potential changes in tariff policy. This digital streamlining empowers contractors to mitigate risks, control costs and gain a competitive edge in an evolving economic landscape."
Trimble Materials integrates with Trimble enterprise resource planning solutions, including Viewpoint Spectrum and Viewpoint Vista, to provide connectivity for contractors to develop more efficient estimating, operations, and accounting management ecosystems.
The solution complements Trimble's existing construction supply chain workflows, which automate the exchange of material pricing between suppliers and contractors and facilitate ordering from preferred suppliers.
With the introduction of Trimble Materials, field users can search for and request materials, view inventory, record received materials, and communicate with the office, the company states.
For office users such as project managers and purchasing teams, the software solution enables more efficient control, approval, and processing of orders, inventory visibility, request for quotation generation, quote comparison, and invoice reconciliation.
The solution is stated to provide a comprehensive view of purchasing activities and spend analysis in one place.
Trimble Materials will be showcased at this year's Construction Financial Management Association National Conference, and will be available as part of the Trimble Construction One software suite for North American contractors.
Last month, Trimble introduced a suite of new application programming interfaces for its cloud-hosted estimating software, Accubid Anywhere.
"Trimble launches new software solution to enhance construction cost control" was originally created and published by World Construction Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Peymo launches AI-driven multi-hybrid banking platform
UK-based fintech innovator Peymo has launched what it claims to be the world's first AI-powered digital banking platform. The multi-hybrid bank is a digital finance platform integrates traditional fiat banking, cryptocurrency wallets, tokenised assets, and embedded finance into a unified system, aiming to streamline the financial management process for users and enterprises. The platform's infrastructure is based on a proprietary modular architecture, which enables users to manage a variety of financial instruments including GBP, EUR, crypto assets, and branded debit cards in a single interface. Furthermore, the system offers APIs that allow businesses to integrate banking functions into their existing operations. Peymo platform features AI-driven voice-first interface, which supports listening, instant intent recognition, and multimodal confirmations to facilitate secure, hands-free banking transactions. The platform employs five specialised AI agents that are responsible for monitoring user behaviour, analysing market activity, optimising payment processes, and safeguarding assets in real time. Additionally, Peymo has incorporated a referral engine that can identify potential new users within a network, send out personalised invitations via communication platforms. It provides instant onboarding using AI and transaction monitoring for expedited clearance, and real-time deposits, with AI also improving of the system's code. The AI technology also aids users in navigating their financial portfolios, which may include a mix of cryptocurrencies, fiat currencies, gold, and tokenised assets. The platform offers a range of features including tokenised payments for instant remittance, multi-currency IBANs for international transactions, a built-in crypto wallet and exchange, and the ability to make contactless crypto payments at physical retail locations. Peymo founder Tomas Bartos said: "We make complex finance invisible. By fusing AI, fiat, crypto and embedded finance into a single stack, we're delivering the next generation of banking — and it's ready today." The core banking system underpinning Peymo's platform has been operational since 2012 and the company is currently seeking to raise €5m in funding and has active letters of intent from potential partners and clients across Africa, Australia, and Europe. "Peymo launches AI-driven multi-hybrid banking platform " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
